Anna Drabik

Dr. Anna Drabik

AGH University of Science and Technology, Krakow MP, Poland
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2017 in Journal of Proteome Research
Verified
Journal Article
Closed access
ADAnna Drabik
Anna Drabik
ABAnna Bodzon-Kulakowska
Anna Bodzon-Kulakowska
PSPiotr Suder
Piotr Suder
JSJerzy Silberring
Jerzy Silberring
JKJan Kulig
Jan Kulig
MSMarek Sierżęga
Marek Sierżęga

25 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
PMPrzemyslaw Mielczarek
Przemyslaw Mielczarek
KHKinga Hartman
Kinga Hartman
ADAnna Drabik
Anna Drabik
HHHao-Yuan Hung
Hao-Yuan Hung
EHEagle Yi-Kung Huang
Eagle Yi-Kung Huang
JSJerzy Silberring
Jerzy Silberring
During the last three decades, a variety of different studies on bioactive peptides that are opioid receptor ligands, have been carried out, with regard to their isolation and identification, as well as their molecular functions in living organisms. Thus, in this review, we would like to summarize the present state-of-the art concerning hemorphins, methodological aspects of their identification, and their potential role as therapeutic agents. We have collected and discussed articles describing hemorphins, from their discovery up until now, thus presenting a very wide spectrum of their characteristic and applications. One of the major assets of the present paper is a combination of analytical and pharmacological aspects of peptides described by a team who participated in the initial research on hemorphins. This review is, in part, focused on the analysis of endogenous opioid peptides in biological samples using advanced techniques, description of the identification of synthetic/endogenous hemorphins, their involvement in pharmacology, learning, pain and other function. Finally, the part regarding hemorphin analogues and their synthesis, has been added.

27 April 2018 in Journal of Proteome Research
Verified
Journal Article
Closed access
ADAnna Drabik
Anna Drabik
JNJoanna Ner-Kluza
Joanna Ner-Kluza
PMPrzemyslaw Mielczarek
Przemyslaw Mielczarek
LCLaia Civit
Laia Civit
GMGünter Mayer
Günter Mayer
JSJerzy Silberring
Jerzy Silberring

1 February 2021 in Peptides
Verified
Journal Article
Closed access
HHHao-Yuan Hung
Hao-Yuan Hung
LCLok-Hi Chow
Lok-Hi Chow
Jolanta H. KotlinskaJolanta H. Kotlinska
Jolanta H. Kotlinska
ADAnna Drabik
Anna Drabik
JSJerzy Silberring
Jerzy Silberring
EHEagle Yi-Kung Huang
Eagle Yi-Kung Huang

21 September 2023 in Materials
Verified
Journal Article
Open access
PDF file
PKPaulina Kret
Paulina Kret
ABAnna Bodzon-Kulakowska
Anna Bodzon-Kulakowska
ADAnna Drabik
Anna Drabik
JNJoanna Ner-Kluza
Joanna Ner-Kluza
PSPiotr Suder
Piotr Suder
MSMarek Smoluch
Marek Smoluch
The science related to biomaterials and tissue engineering accounts for a growing part of our knowledge. Surface modifications of biomaterials, their performance in vitro, and the interaction between them and surrounding tissues are gaining more and more attention. It is because we are interested in finding sophisticated materials that help us to treat or mitigate different disorders. Therefore, efficient methods for surface analysis are needed. Several methods are routinely applied to characterize the physical and chemical properties of the biomaterial surface. Mass Spectrometry Imaging (MSI) techniques are able to measure the information about molecular composition simultaneously from biomaterial and adjacent tissue. That is why it can answer the questions connected with biomaterial characteristics and their biological influence. Moreover, this kind of analysis does not demand any antibodies or dyes that may influence the studied items. It means that we can correlate surface chemistry with a biological response without any modification that could distort the image. In our review, we presented examples of biomaterials analyzed by MSI techniques to indicate the utility of SIMS, MALDI, and DESI—three major ones in the field of biomaterials applications. Examples include biomaterials used to treat vascular system diseases, bone implants with the effects of implanted material on adjacent tissues, nanofibers and membranes monitored by mass spectrometry-related techniques, analyses of drug-eluting long-acting parenteral (LAPs) implants and microspheres where MSI serves as a quality control system.

9 October 2013 in Molecular and Cellular Biochemistry
Verified
Journal Article
Open access
PDF file
ADAnna Drabik
Anna Drabik
DCDorota Ciołczyk-Wierzbicka
Dorota Ciołczyk-Wierzbicka
JDJoanna Dulińska-Litewka
Joanna Dulińska-Litewka
ABAnna Bodzon-Kulakowska
Anna Bodzon-Kulakowska
PSPiotr Suder
Piotr Suder
PLPiotr Laidler
Piotr Laidler
Prostate cancer is one of the most common malignancies in men and is predicted to be the second leading cause of cancer-related deaths. After 6–18 months, hormone ablation treatment results in androgen-independent growth of cancer cells, metastasis and progression. The mechanism of androgen-independent growth of prostatic carcinoma cells is still unknown. Identification of factors that facilitate the transition from androgen-dependent to independent states is crucial in designing future diagnostics and medication strategies. To understand the biochemical meaning of hormone dependency deprivation, glycoproteins enriched profiles were compared between DU145 (hormone non-responding) and LNCaP (hormone responding) prostate cancer cells. These results allow for anticipation on the important role of glycosylation in malignant transformation. Both Tn antigen and complex antennary N-oligosaccharides were recognized. Their occurrence might be involved in the development and progression of tumor, and failure of hormone ablation therapy. Among identified proteins in androgen-sensitive cells nucleolin (P19338) was found that is widely described as apoptosis inhibitor, and also transporter of molecules from the membrane to the cytoplasm or nucleus. In addition, 14-3-3 protein family (P27348, P31946, P61981, P63104, P62258, Q04917, and P31947) was investigated across available databases as it forms stable complexes with glycoproteins. Our studies indicate that isoforms: sigma and eta were found in androgen-dependent prostate cancer cells, while other isoforms were present in androgen non-responding cells. 14-3-3 binding partners are involved in cancer pathogenesis. These findings may contribute to a better understanding of prostate cancer tumorigenesis and to a more efficient prognosis and individual therapy in a future. However, it still remains to be revealed how important those changes are for androgen dependency loss in prostate cancer patients carried out on clinically relevant populations.